Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants

Recruiting Observational Study
Germline Mutation Myelodysplastic Syndromes Acute Myeloid Leukemia
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
1 Month – 120
Sex
Any
Study type
Observational
Participants needed
510 (estimated)
Sponsor
National Cancer Institute (NCI) · NIH
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Background: Hereditary hematopoietic malignancy (HHM) syndromes are a group of inherited disorders that raises the risk of blood cancers. Many people with HHMs have changes in a gene (DDX41) that makes it more likely that they will develop myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), or other cancers. This natural history study will explore the link between HHM syndromes and thes…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
* INCLUSION CRITERIA: * Age \> 1 month old. * Participants with history of aberrations that affect the DDX41 gene, DDX41 RNA, or DDX41 protein (Cohorts 1-2) OR Participants with history of aberrations in another HHM variant (Cohort 3) OR Participants with history of absence of HHM variants, who …
Contacts

Rebecca B Alexander

(240) 781-4037

rebecca.alexander@nih.gov

CONTACT

Sung-Yun Pai, M.D.

(240) 858-7284

sung-yun.pai@nih.gov

CONTACT